Clinical Trial Update: A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults [Phase 1]

View source ↗

Summary

Pfizer conducted a Phase 1 trial to evaluate a pneumococcal vaccine that includes a novel ingredient (PF-07872411) intended to enhance vaccine effectiveness in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PF-07872411

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 1 | Status: COMPLETED